Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cyclo Therapeutics Inc
(NQ:
CYTH
)
0.7300
+0.0310 (+4.43%)
Streaming Delayed Price
Updated: 3:56 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
18,086
Open
0.7000
Bid (Size)
0.6900 (30)
Ask (Size)
0.7300 (8)
Prev. Close
0.6990
Today's Range
0.6811 - 0.7700
52wk Range
0.5946 - 2.115
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
November 06, 2024
Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Performance
YTD
-56.02%
-56.02%
1 Month
-2.67%
-2.67%
3 Month
-6.41%
-6.41%
6 Month
-45.93%
-45.93%
1 Year
-43.41%
-43.41%
More News
Read More
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
October 21, 2024
From
Pacira BioSciences
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
September 06, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
September 05, 2024
From
Cyclo Therapeutics
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders
August 27, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
August 27, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
This Hershey Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
August 27, 2024
Via
Benzinga
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
August 26, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, SDIG, ARCH, CYTH on Behalf of Shareholders
August 24, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results
August 22, 2024
Via
Benzinga
Gold Down Over 1%; US Initial Jobless Claims Increase
August 22, 2024
Via
Benzinga
CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders
August 22, 2024
From
Halper Sadeh LLC
Via
Business Wire
Dow Jumps 100 Points; BJ's Wholesale Earnings Top Estimates
August 22, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
August 22, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
August 22, 2024
From
Rafael Holdings, Inc.; Cyclo Therapeutics
Via
GlobeNewswire
CYTH Stock Earnings: Cyclo Therapeutics Misses EPS, Misses Revenue for Q2 2024
August 15, 2024
Via
InvestorPlace
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 15, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
July 29, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
June 25, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
June 14, 2024
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
May 30, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q1 2024
May 16, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
April 18, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.